These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 28799536)
1. Estrogen receptor (ESR1) mutation in bone metastases from breast cancer. Bartels S; Christgen M; Luft A; Persing S; Jödecke K; Lehmann U; Kreipe H Mod Pathol; 2018 Jan; 31(1):56-61. PubMed ID: 28799536 [TBL] [Abstract][Full Text] [Related]
2. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials. Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985 [TBL] [Abstract][Full Text] [Related]
3. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1). Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563 [TBL] [Abstract][Full Text] [Related]
4. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer. Christgen M; Bartels S; Luft A; Persing S; Henkel D; Lehmann U; Kreipe H Virchows Arch; 2018 Nov; 473(5):577-582. PubMed ID: 30094493 [TBL] [Abstract][Full Text] [Related]
5. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237 [TBL] [Abstract][Full Text] [Related]
6. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597 [TBL] [Abstract][Full Text] [Related]
8. ESR1 genetic alterations and their association with clinicopathologic characteristics in advanced breast cancer: a single academic institution experience. Freitag CE; Mei P; Wei L; Parwani AV; Li Z Hum Pathol; 2021 Jan; 107():80-86. PubMed ID: 33157125 [TBL] [Abstract][Full Text] [Related]
9. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954 [TBL] [Abstract][Full Text] [Related]
10. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408 [TBL] [Abstract][Full Text] [Related]
11. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332 [TBL] [Abstract][Full Text] [Related]
12. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794 [TBL] [Abstract][Full Text] [Related]
13. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients. Franken A; Honisch E; Reinhardt F; Meier-Stiegen F; Yang L; Jaschinski S; Esposito I; Alberter B; Polzer B; Huebner H; Fasching PA; Pancholi S; Martin LA; Ruckhaeberle E; Schochter F; Tzschaschel M; Hartkopf AD; Mueller V; Niederacher D; Fehm T; Neubauer H J Mol Diagn; 2020 Jan; 22(1):111-121. PubMed ID: 31669227 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364 [TBL] [Abstract][Full Text] [Related]
15. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors. Leal MF; Haynes BP; Schuster E; Yeo B; Afentakis M; Zabaglo L; Martins V; Buus R; Dodson A; Cheang MCU; Smith IE; Martin LA; Dowsett M Clin Cancer Res; 2019 Dec; 25(24):7485-7496. PubMed ID: 31548345 [TBL] [Abstract][Full Text] [Related]
16. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H Transl Res; 2015 Dec; 166(6):540-553.e2. PubMed ID: 26434753 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700 [TBL] [Abstract][Full Text] [Related]
18. Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Clatot F; Perdrix A; Augusto L; Beaussire L; Delacour J; Calbrix C; Sefrioui D; Viailly PJ; Bubenheim M; Moldovan C; Alexandru C; Tennevet I; Rigal O; Guillemet C; Leheurteur M; Gouérant S; Petrau C; Théry JC; Picquenot JM; Veyret C; Frébourg T; Jardin F; Sarafan-Vasseur N; Di Fiore F Oncotarget; 2016 Nov; 7(46):74448-74459. PubMed ID: 27801670 [TBL] [Abstract][Full Text] [Related]
19. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing. Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903 [TBL] [Abstract][Full Text] [Related]
20. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients. Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]